← Leaderboards
Paul Spearman
Emory University
$5,058,409
Attributed
$5,058,409
Total exposure
1
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $4.1M · FY2015–20$5M$3.8M$2.5M$1.3M$0
'15
'16
'17
'18
'19
'20
Funding mix
By agency
NIH$5,058,409 · 1
By mechanism
N01$5,058,409 · 1
Top collaborators
No co-investigators on record.
Most similar at Emory University
Same institution · by research overlap
- Steven M Hersch$23,995,705
- David S Stephens$107,429,191
- Kathleen Maletic Neuzil$28,253,585
- Suresh S Ramalingam$10,859,222
- Mandy L. Ford$29,844,446
Others in their field
Top investigators on “Vaccines”
- Lawrence Corey · Fred Hutchinson Cancer Center$829,044,908
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$556,540,832
- Bambra Strokes · Ppd Development Lp$526,656,217
- Barton F Haynes · Duke University$515,215,260
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$398,445,678
- Dennis R. Burton · Scripps Research Institute$316,106,418
Research focus
VaccinesContractsDesignEbola VirusEvaluationConduct Clinical TrialsFilovirusFrankfurt-Marburg Syndrome VirusInfectious Disease TreatmentInvestigationNamed GroupPhase I TrialResourcesRouteFiloviridae
Grant awards (4)
Vaccine and Treatment Evaluation Unit: Phase I Trial of Filovirus Vaccine$583,291
N01 · FY2020 · AI · contact PI
Vaccine and Treatment Evaluation Unit: Phase I Trial of Filovirus Vaccine$49,650
N01 · FY2018 · AI · contact PI
Vaccine and Treatment Evaluation Unit: Phase I Trial of Filovirus Vaccine$327,462
N01 · FY2017 · AI · contact PI
Phase I Trial of Filovirus Vaccine - VTEU$4,098,006
N01 · FY2015 · AI · contact PI